Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Minodronate Alone Improves BMD in Patients with Osteoporosis and Rheumatoid Arthritis
Key clinical point: Minodronate monotherapy could be considered for improving bone mineral density in patients with osteoporosis and rheumatoid arthritis.
Major finding: Bone alkaline phosphatase decreased from 6 to 18 months in the minodronate-alone versus the minodronate-plus-eldecalcitol group, with a significant difference between the groups at 6 months (–40% vs. –15%, respectively).
Study details: Prospective, 18-month, observational study of 28 women with osteoporosis and rheumatoid arthritis activity, divided into 2 groups to receive minodronate alone or minodronate plus eldecalcitol (vitamin D).
Disclosures: Ono Pharmaceutical funded the study. The authors reported no conflicts of interest.
Suzuki T et al. Osteoporos Sarcopenia. 2019 Dec 16. doi: 10.1016/j.afos.2019.11.004.